For one, the pink generic Adderall was noticeably different from its orange predecessor. Moreover, I simply do not believe the standard industry line that generic medications are “exactly the same” as their branded counterparts, given the leeway that generic drug producers have when it comes to binders and fillers.
The thousands of responses I received to my posts on this topic indicate that others tend to agree. I’m wondering if some of these same issues arose (or are arising) with the generic extended release form of Adderall.
But it’s also noteworthy that Teva was sued by Shire Laboratories in 2006 over patent issues. Shire was the original patent holder for brand named Adderall. It was around that time that many of us first began to notice the difference between generic and brand Adderall. (I sure hope the clowns at CorePharma weren’t tinkering with the recipe to avoid lawsuits.)
I can’t speak from personal experience regarding Teva’s new generic Adderall XR, but early reports from friends and associates of mine are that “The timed release went generic and now it sucks.”
The Food & Drug Administration has a contact page. People who notice these sorts of problems are encouraged to notify the FDA.